专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09133082B2 Opsin-binding ligands, compositions and methods of use 有权
标题翻译：组氨酸 - 结合配体，组合物和使用方法
公开(公告)号：US09133082B2
公开(公告)日：2015-09-15
申请号：US14126177
申请日：2012-06-13
申请人： David S. Garvey
发明人： David S. Garvey
IPC分类号： C07C25/06 , C07D333/16 , C07D333/22 , C07D307/42 , C07D307/46 , C07C33/14 , C07C33/34 , C07C33/50 , C07C43/23 , C07C255/53 , C07C255/56 , C07C259/18 , C07C25/18 , C07C25/13 , C07C49/792 , C07C49/813 , C07C49/84
CPC分类号： C07D333/22 , A61K31/045 , A61K31/12 , A61K31/277 , C07C25/06 , C07C25/13 , C07C25/18 , C07C33/14 , C07C33/34 , C07C33/50 , C07C43/23 , C07C49/792 , C07C49/813 , C07C49/84 , C07C255/53 , C07C255/56 , C07C259/18 , C07C2601/14 , C07C2601/16 , C07D307/42 , C07D307/46 , C07D333/16
摘要： Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.
摘要翻译：公开的化合物可用于治疗由眼睛中累积的毒性视觉循环产物引起或与其相关的眼部疾病，例如干性成人黄斑变性，以及由突变视蛋白质蛋白质错误折叠引起或与之相关的病症，以及 /或视蛋白蛋白质的错位。还描述了这些化合物单独或与其它治疗剂组合的组合物，以及使用这些化合物和/或组合物的治疗方法。还公开了合成这些试剂的方法。

2. 发明授权

US08846674B2 Nitric oxide enhancing prostaglandin compounds, compositions and methods of use 有权
标题翻译：一氧化氮增强型前列腺素化合物，组合物和使用方法
公开(公告)号：US08846674B2
公开(公告)日：2014-09-30
申请号：US13275768
申请日：2011-10-18
申请人： David S. Garvey
发明人： David S. Garvey
IPC分类号： A61K31/5377 , A61K31/4523 , A61K31/41 , A61K31/4245 , A61K31/4035 , A61K31/535 , C07D233/02 , C07D271/08 , C07D263/06 , C07D265/06 , C07D211/94 , C07D209/46 , C07D207/46
CPC分类号： C07D271/08 , C07D207/46 , C07D209/46 , C07D211/94 , C07D233/02 , C07D263/06 , C07D265/06
摘要： The invention provides methods for treating ophthalmic disorders comprising at least one nitric oxide enhancing prostaglandin compound or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The nitric oxide enhancing prostaglandin compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group.
摘要翻译：本发明提供治疗眼科疾病的方法，其包含至少一种一氧化氮增强性前列腺素化合物或其药学上可接受的盐，和任选的至少一种一氧化氮增强化合物和/或至少一种治疗剂。一氧化氮增强型前列腺素化合物包含至少一种杂环一氧化氮供体基团和/或至少一种氮氧化物基团。

3. 发明申请

US20120034321A1 NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE 有权
标题翻译：硝酸氧化物增强前体化合物，组合物和使用方法
公开(公告)号：US20120034321A1
公开(公告)日：2012-02-09
申请号：US13275768
申请日：2011-10-18
申请人： David S. Garvey
发明人： David S. Garvey
IPC分类号： A61K33/00 , A61K31/41 , A61K31/5377 , A61K31/454 , A61K31/535 , A61K31/421 , A61K31/4035 , A61K31/19 , A61K31/192 , A61K31/18 , A61K31/216 , A61P27/02 , A61K31/56 , A61P3/10 , A61P31/00 , A61P3/06 , A61P7/02 , A61P9/08 , A61P7/10 , A61P29/00 , A61P27/06 , A61K31/4245
CPC分类号： C07D271/08 , C07D207/46 , C07D209/46 , C07D211/94 , C07D233/02 , C07D263/06 , C07D265/06
摘要： The invention provides methods for treating ophthalmic disorders comprising at least one nitric oxide enhancing prostaglandin compound or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The nitric oxide enhancing prostaglandin compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group.
摘要翻译：本发明提供治疗眼科疾病的方法，其包含至少一种一氧化氮增强性前列腺素化合物或其药学上可接受的盐，和任选的至少一种一氧化氮增强化合物和/或至少一种治疗剂。一氧化氮增强型前列腺素化合物包含至少一种杂环一氧化氮供体基团和/或至少一种氮氧化物基团。

4. 发明授权

US07838023B2 Furoxan compounds, compositions and methods of use 失效
标题翻译：呋喃糖化合物，组合物和使用方法
公开(公告)号：US07838023B2
公开(公告)日：2010-11-23
申请号：US12093561
申请日：2006-11-16
申请人： David S. Garvey , Ramani R. Ranatunge
发明人： David S. Garvey , Ramani R. Ranatunge
IPC分类号： A61K9/00 , A61K31/4245 , A61K31/502 , A61K33/00 , A61P9/00 , C07D271/08
CPC分类号： C07D271/08
摘要： The invention provides novel furoxan compounds, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for (a) treating cardiovascular diseases; (b) inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device; (c) treating pathological conditions resulting from abnormal cell proliferation; (d) treating transplantation rejections, (e) treating autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; (f) reducing scar tissue or for inhibiting wound contraction; (g) treating diseases resulting from oxidative stress; (h) treating endothelial dysfunctions; and (j) treating diseases caused by endothelial dysfunctions.
摘要翻译：本发明提供新的呋喃糖化合物或其药学上可接受的盐，以及包含至少一种化合物和任选的至少一种一氧化氮增强化合物和/或至少一种治疗剂的新组合物。本发明的化合物和组合物也可以结合到基质上。本发明还提供了（a）治疗心血管疾病的方法; （b）抑制由血液暴露于医疗器械引起的血小板聚集和血小板粘附; （c）治疗由异常细胞增殖引起的病理状况; （d）治疗移植排斥，（e）治疗自身免疫性，炎症性，增殖性，过度增殖性或血管性疾病; （f）减少瘢痕组织或抑制伤口收缩; （g）治疗由氧化应激引起的疾病; （h）治疗内皮功能障碍; 和（j）治疗由内皮功能障碍引起的疾病。

5. 发明申请

US20100137291A1 NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE 有权
公开(公告)号：US20100137291A1
公开(公告)日：2010-06-03
申请号：US12636316
申请日：2009-12-11
申请人： Richard A. EARL , Maiko EZAWA , Xinqin FANG , David S. GARVEY , Ricky D. GASTON , Subhash P. KHANAPURE , L. Gordon LETTS , Chia-En LIN , Ramani R. RANATUNGA , Stewart K. RICHARDSON , Joseph D. SCHROEDER , Cheri A. STEVENSON , Shiow-Jyi WEY
发明人： Richard A. EARL , Maiko EZAWA , Xinqin FANG , David S. GARVEY , Ricky D. GASTON , Subhash P. KHANAPURE , L. Gordon LETTS , Chia-En LIN , Ramani R. RANATUNGA , Stewart K. RICHARDSON , Joseph D. SCHROEDER , Cheri A. STEVENSON , Shiow-Jyi WEY
IPC分类号： A61K31/5415 , A61K31/437 , A61K31/436 , A61K31/426 , A61K31/421 , A61K31/416 , A61K31/404 , A61K31/40 , A61K31/381 , C07D279/22 , C07D263/56 , C07D231/56 , C07D231/10 , C07D491/052 , C07D209/34 , C07D209/12 , C07D333/22 , A61P35/00 , A61P1/00 , A61P29/00
CPC分类号： C07D493/04 , C07C291/02 , C07C311/17 , C07C317/18 , C07C323/12 , C07C327/28 , C07D209/18 , C07D211/22 , C07D211/56
摘要： The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

6. 发明申请

US20090088366A1 NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE 失效
标题翻译：硝基和硝基化前体，组合物和使用方法
公开(公告)号：US20090088366A1
公开(公告)日：2009-04-02
申请号：US12237117
申请日：2008-09-24
申请人： David S. Garvey , Ricky D. Gaston , Inigo Saenz de Tejada , Sang William Tam , Manuel Worcel
发明人： David S. Garvey , Ricky D. Gaston , Inigo Saenz de Tejada , Sang William Tam , Manuel Worcel
IPC分类号： A61K38/02 , A61K31/215 , A61K31/4164 , A61K31/4375 , A61P15/00 , A61K31/496 , A61K31/7076
CPC分类号： A61K31/5575
摘要： The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的前列腺素，以及包含至少一种亚硝化和/或亚硝基化的前列腺素的新组合物，以及任选的至少一种捐赠，转移或释放一氧化氮的化合物，提高内源性内皮水平的放松因子，刺激一氧化氮的内源性合成或是一氧化氮合酶的底物和/或至少一种血管活性剂。本发明还提供了包含至少一种前列腺素和至少一种S-亚硝基硫醇化合物和任选的至少一种血管活性剂的新型组合物。前列腺素优选为前列腺素E1化合物，更优选前列地尔，S-亚硝基硫醇化合物优选为S-亚硝基谷胱甘肽。本发明还提供用于治疗或预防男性和女性的性功能障碍的方法，用于增强男性和女性的性反应，以及用于治疗或预防脑血管疾病，心血管疾病，良性前列腺增生（BPH），青光眼，消化性溃疡或诱导堕胎

7. 发明申请

US20090053328A1 Nitric Oxide Enhancing Glutamic Acid Compounds, Compositions and Methods of Use 审中-公开
标题翻译：一氧化氮增强谷氨酸化合物，组合物和使用方法
公开(公告)号：US20090053328A1
公开(公告)日：2009-02-26
申请号：US12096328
申请日：2006-12-19
申请人： David S. Garvey
发明人： David S. Garvey
IPC分类号： A61K33/00 , C07D271/04 , A61K31/4245 , C07D413/12 , A61K31/5377
CPC分类号： A61K31/4245
摘要： The invention provides novel compositions and kits comprising at least one nitric oxide enhancing glutamic acid compound, or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension (n) treating diseases resulting from elevated levels of gamma-glutamyl transpeptidase and (O) the targeted delivery of compounds and nitric oxide to organs, cells or tissues containing the enzyme gamma-glutamyl transpeptidase. The nitric oxide enhancing glutamic acid compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group.
摘要翻译：本发明提供了包含至少一种一氧化氮增强型谷氨酸化合物或其药学上可接受的盐，以及任选的至少一种一氧化氮增强化合物和/或至少一种治疗剂的新型组合物和试剂盒。本发明还提供了（a）治疗心血管疾病的方法; （b）治疗血管性疾病; （c）治疗糖尿病; （d）治疗由氧化应激引起的疾病; （e）治疗内皮功能障碍; （f）治疗由内皮功能障碍引起的疾病; （g）治疗肝硬化; （h）治疗先兆子痫; （j）治疗骨质疏松症; （k）治疗肾病; （l）治疗外周血管疾病; （m）治疗门静脉高压（n）治疗由γ-谷氨酰转肽酶水平升高引起的疾病，和（O）将化合物和一氧化氮靶向递送至含有γ-谷氨酰转肽酶的器官，细胞或组织。一氧化氮增强型谷氨酸化合物包含至少一种杂环一氧化氮供体基团和/或至少一种氮氧自由基。

8. 发明申请

US20090048219A1 ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：非甾体抗炎药物的有机氮氧化物钠盐，组合物和使用方法
公开(公告)号：US20090048219A1
公开(公告)日：2009-02-19
申请号：US11914204
申请日：2006-05-23
申请人： David S. Garvey
发明人： David S. Garvey
IPC分类号： A61K31/56 , C07D271/04 , A61K31/4245 , A61K31/5415 , C07D417/14 , C07D401/14 , C07D271/08 , A61P1/00 , A61P17/02 , A61P27/02 , A61P11/00 , A61P9/00 , A61P35/00 , C07D413/02 , A61K31/5377 , A61K31/4439 , C07D401/02 , A61K31/454 , A61K31/496
CPC分类号： C07C229/42 , C07C57/58 , C07C59/64 , C07C59/68 , C07C59/84 , C07C59/86 , C07C59/88 , C07C313/36 , C07D209/12 , C07D263/32 , C07D277/24 , C07D279/12 , C07D333/22 , C07D471/04 , C07D498/04
摘要： The invention describes novel organic nitric oxide enhancing salts of nonsteroidal antiinflammatory drugs (NSAIDs) and novel compositions comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating inflammation, pain and fever; (b) treating gastrointestinal disorders; (c) facilitating wound healing; (d) treating gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; (e) treating inflammatory disease states and/or disorders; (f) treating ophthalmic disorders; (h) treating peripheral vascular diseases; (i) treating diseases resulting from oxidative stress; (j) treating endothelial dysfunctions; and (k) treating diseases caused by endothelial dysfunctions. The organic nitric oxide enhancing compounds that form salts with the NSAIDs are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.
摘要翻译：本发明描述了非甾体抗炎药（NSAID）的新型有机一氧化氮增强盐和包含至少一种NSAID的有机一氧化氮增强盐，和任选地至少一种一氧化氮增强化合物和/或至少一种治疗代理商本发明还提供了包含NSAID的至少一种有机一氧化氮增强盐和任选的至少一种一氧化氮增强化合物和/或至少一种治疗剂的新型组合物和试剂盒。本发明还提供了（a）治疗炎症，疼痛和发烧的方法; （b）治疗胃肠道疾病; （c）促进伤口愈合; （d）治疗由使用非甾体抗炎化合物引起的胃肠道，肾脏和/或呼吸道毒性; （e）治疗炎性疾病状态和/或病症; （f）治疗眼科疾病; （h）治疗外周血管疾病; （i）治疗由氧化应激引起的疾病; （j）治疗内皮功能障碍; 和（k）治疗由内皮功能障碍引起的疾病。与NSAID形成盐的有机一氧化氮增强化合物是有机硝酸盐，有机亚硝酸盐，亚硝基硫醇，硫堇啶，硫堇酸盐，非硝酸盐，杂环一氧化氮供体和/或氮氧化物。杂环一氧化氮供体是呋喃糖，苏氨酸，氧杂三唑-5-酮和/或氧杂三唑-5-亚胺。

9. 发明申请

US20090005350A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译： CYCLOOXYGENASE-2选择性抑制剂，组合物和使用方法
公开(公告)号：US20090005350A1
公开(公告)日：2009-01-01
申请号：US12210776
申请日：2008-09-15
申请人： Upul K. Bandarage , Richard A. Earl , Maiko Ezawa , Xinqin Fang , David S. Garvey , Subhash P. Khanapure , Ramani R. Ranatunge , Stewart K. Richardson , Joseph D. Schroeder , Cheri A. Stevenson , Shiow-Jyi Wey
发明人： Upul K. Bandarage , Richard A. Earl , Maiko Ezawa , Xinqin Fang , David S. Garvey , Subhash P. Khanapure , Ramani R. Ranatunge , Stewart K. Richardson , Joseph D. Schroeder , Cheri A. Stevenson , Shiow-Jyi Wey
IPC分类号： A61K31/60 , A61K31/415 , C07D231/10
CPC分类号： C07D231/12 , C07D261/08 , C07D401/04
摘要： The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.
摘要翻译：本发明描述了新型环氧合酶2（COX-2）选择性抑制剂和包含至少一种环氧合酶2（COX-2）选择性抑制剂的新型组合物，以及任选地至少一种捐赠，转移或释放一氧化氮的化合物，刺激内源性合成的一氧化氮，提高内源性内源性释放因子水平，或者是一氧化氮合酶的底物和/或至少一种治疗剂。本发明还提供了包含至少一种COX-2选择性抑制剂，任选地亚硝基化和/或亚硝基化的新的试剂盒，以及任选的至少一种一氧化氮供体，和/或任选的至少一种治疗剂。本发明的新型环加氧酶2选择性抑制剂可以任选地亚硝化和/或亚硝化。本发明还提供了治疗炎症，疼痛和发烧的方法; 用于治疗和/或改善COX-2选择性抑制剂的胃肠性质; 促进伤口愈合; 用于治疗和/或预防肾和/或呼吸毒性; 用于治疗和/或预防由环氧合酶-2水平升高引起的其他疾病; 并用于改善COX-2选择性抑制剂的心血管外形。

10. 发明申请

US20080293678A1 Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use 审中-公开
标题翻译：血管紧张素转换酶抑制剂，组合物和使用方法的有机一氧化氮供体盐
公开(公告)号：US20080293678A1
公开(公告)日：2008-11-27
申请号：US11886461
申请日：2006-03-17
申请人： David S. Garvey
发明人： David S. Garvey
IPC分类号： C07D271/08 , C07D207/00 , A61K31/40 , A61K31/675 , C07F9/572 , C07D209/02 , A61K31/403 , A61K31/407 , C07D495/10 , C07D223/14 , A61K31/55 , A61K31/551 , A61K31/554 , C07D487/04 , C07D281/02 , C07D233/00 , A61K31/4166 , A61K31/47 , A61P9/00 , C07D413/00 , C07D217/00 , A61K31/216 , C07C229/00 , C07D295/00 , A61K31/5375 , A61K31/44 , C07D213/56 , C07C291/02 , A61K31/04 , A61K31/41
CPC分类号： C07D207/16
摘要： The invention describes compositions and kits comprising at least qrie organic nitric oxide enhancing salt of an angiotensin converting enzyme inhibitor, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; Q) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The organic nitric oxide enhancing compounds that form salts with the angiotensin converting enzyme inhibitors are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.
摘要翻译：本发明描述了包含血管紧张素转换酶抑制剂的至少有机一氧化氮增强盐，和任选的至少一种一氧化氮增强化合物和/或至少一种治疗剂的组合物和试剂盒。本发明还提供了（a）治疗心血管疾病的方法; （b）治疗血管性疾病; （c）治疗糖尿病; （d）治疗由氧化应激引起的疾病; （e）治疗内皮功能障碍; （f）治疗由内皮功能障碍引起的疾病; （g）治疗肝硬化; （h）治疗先兆子痫; Q）治疗骨质疏松症; （k）治疗肾病; （l）治疗外周血管疾病; （m）治疗门静脉高压; （n）治疗眼科疾病; （o）治疗代谢综合征; 和（p）治疗高脂血症。与血管紧张素转换酶抑制剂形成盐的有机一氧化氮增强化合物是有机硝酸盐，有机亚硝酸盐，亚硝基硫醇，硫堇啶，硫堇酸盐，非硝酸盐，杂环一氧化氮供体和/或氮氧化物。杂环一氧化氮供体是呋喃糖，苏氨酸，氧杂三唑-5-酮和/或氧杂三唑-5-亚胺。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式